SCHEMBL10036086

SCHEMBL10036086

C=CCN1C(=O)/C(=C2/Sc3ccccc3N2CCC(=O)O)SC1=S

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 13/20 0.72
▸ KMT2A Q03164 13/20 0.72
▸ POLB P06746 5/20 0.72
▸ MMP13 P45452 2/20 0.71
▸ MAPT P10636 2/20 0.66
▸ ALOX15 P16050 2/20 0.66
▸ ALOX12 P18054 2/20 0.66
▸ CASP1 P29466 2/20 0.66
▸ CASP7 P55210 2/20 0.66
▸ HSD17B10 Q99714 2/20 0.66
▸ CTDSP1 Q9GZU7 2/20 0.66
▸ ALDH1A1 P00352 1/20 0.66
▸ L3MBTL1 Q9Y468 1/20 0.66
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ LMNA P02545 2/20 0.52
▸ APEX1 P27695 1/20 0.51
▸ HPGD P15428 1/20 0.48
▸ CISD1 Q9NZ45 2/20 0.47
▸ MAOA P21397 1/20 0.47
▸ PTPN7 P35236 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10661708 0.84 MEN1 (0.76) MEN1KMT2APOLBMMP13MAPT
SCHEMBL9054686 0.84 MEN1 (0.60) MEN1KMT2APOLBMMP13MAPT
SCHEMBL9054683 0.84 MEN1 (0.60) MEN1KMT2APOLBMMP13MAPT
SCHEMBL9650252 0.83 MEN1 (0.79) MEN1KMT2APOLBMMP13MAPT
SCHEMBL9650247 0.83 MEN1 (0.79) MEN1KMT2APOLBMMP13MAPT
SCHEMBL10036089 0.77 KMT2A (0.46) MEN1KMT2APOLBMMP13MAPT
SCHEMBL8606929 0.76 MEN1 (0.61) MEN1KMT2APOLBMMP13MAPT
SCHEMBL8606927 0.76 MEN1 (0.61) MEN1KMT2APOLBMMP13MAPT
SCHEMBL9191085 0.75 MEN1 (0.80) MEN1KMT2APOLBMMP13MAPT
SCHEMBL9191082 0.75 MEN1 (0.80) MEN1KMT2APOLBMMP13MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 MEN1 2218/4885KMT2A 2624/4885POLB 2015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback